Stem cell yield and characteristics
Stem cell properties of AMPCs
- Self-renewing cells have multidirectional differentiation potential
- Transformed from adult white blood cells, the number of stem cells is between 3 × 108 and 1 × 109
- Contains a variety of stem cells, including hematopoietic stem cells, mesenchymal stem cells, endothelial stem cells, and very small embryonic stem cells (VSEL)
- It has a homing effect, can identify the parts of the body that need to be repaired, perform stem cell regeneration, and activate the body to transmit chemical signals
Multiple functions of AMPCs
- After proper induction, it has the potential to transform into neural cells (ectoderm), osteoblasts (mesoderm), cardiomyocytes (mesoderm) and hepatocytes (endoderm)
Different advantages of AMPCs over other stem cells
- It has a broad differentiation potential and can assist in the treatment of most degenerative diseases, including arthritis, leukemia, cardiovascular disease, kidney disease or liver disease, and some autoimmune diseases.
- The homing effect of stem cell therapy can identify autologous areas that need priority regeneration
- The insurance coverage during clinical treatment can provide complete protection for patients and performing doctors (no claims have been made so far)
Safety of stem cells
- The cell processing method is a closed system, which fully reduces the risk of contamination
- Safe cell production process, no growth factors added, and still high number of stem cells
- Safe cell production process, no gene amplification and reprinting, but still has the high plasticity of stem cells
- After animal tests on tumorigenicity, it was confirmed that AMPC would not form any tumors
- AMPCs showed pluripotency, differentiation characteristics and self-renewal ability, but the embryonic stem cell markers SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81 were not detected.
- AMPC is tested by a testing laboratory accredited by the National Testing Association of Australia (NATA) for microbiological testing.
- AMPC will be recognized by the World Anti-Doping Agency in 2023, allowing Olympic athletes to perform autologous infusions of AMPC
- The production laboratory complies with ISO9001:2008 quality assurance standards
- Approved by the Australian TGA, it complies with the minimum operation requirements of the production process in cell therapy
- Obtained Australian Therapeutic Goods Registration Exemption Permit in 2011